Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Jonathan Chou, MD, PhD

Photo of Jonathan Chou, MD, PhD
Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
Address10 Koret Way, #235
San Francisco CA 94117
Phone415-476-1314
PronounsHe/Him/His
ORCID ORCID Icon0000-0003-1258-0391 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    Stanford University, Stanford, CABS06/2005Biological Sciences, Chemistry
    UCSF, San Francisco, CAPhD09/2012Biomedical Sciences
    UCSF, San Francisco, CAMD06/2014Medicine
    UCSF, San Francisco, CA06/2016Resident, Internal Medicine
    UCSF, San Francisco, CA06/2020Fellowship, Medical Oncology
    Collapse awards and honors
    American Society for Clinical Investigation (ASCI)2026Young Physician Scientist Award
    Damon Runyon Cancer Foundation2025Clinical Investigator Award
    The V Foundation2025V Scholar Award
    Bladder Cancer Advocacy Network (BCAN)2023Young Investigator Award
    UCSF Prostate Cancer Program2023UCSF Prostate Pilot Award
    Prostate Cancer Foundation2020Young Investigator Award
    Department of Defense, Prostate Cancer Research Program2019Physician Research Award
    UCSF, Division of Hematology/Oncology2018Rosenberg Fellowship in Genitourinary Oncology
    A.P. Giannini Foundation2018A.P. Giannini Postdoctoral Fellow
    UCSF, Division of Hematology/Oncology2017Clinical Fellow Award
    UCSF, Helen Diller Cancer Center2017T32 Fellow in Molecular and Cellular Mechanisms of Cancer
    UCSF, Division of Hematology/Oncology2017Quinlan Fellowship in Genitourinary Oncology
    Stanford University2006Dean's Award for Academic Accomplishment
    Stanford University2006Firestone Medal for Undergraduate Thesis
    Goldwater Foundation2003Goldwater Scholar

    Collapse Overview 
    Collapse overview
    I am a physician-scientist in the Division of Hematology/Oncology and an attending physician in the Genitourinary Medical Oncology Clinic at UCSF. Our lab is interested in multiple areas of cancer biology and translational oncology. Our current research projects include developing novel CAR T and radioimmunotherapies for prostate and bladder cancers (including identifying new therapeutic targets using transcriptomic and proteomic approaches), and understanding resistance mechanisms to antibody-drug conjugates and other surface-protein targeting modalities. In addition, we are interested in the role of CDK12 in regulating transcription and replication, and identifying new therapeutic approaches to treat this aggressive subtype of disease. I completed my postdoctoral research fellowship with Drs. Felix Feng and Alan Ashworth and my clinical training with Drs. Eric Small, Terence Friedlander and Chuck Ryan. I completed my PhD dissertation in the Biomedical Sciences program at UCSF with the late Dr. Zena Werb, and studied transcriptional regulation of metastasis and the tumor microenvironment.
    Collapse Mentoring

    Collapse Research 
    Collapse research activities and funding
    Strategies to upregulate and image NECTIN4 to enhance NECTIN4 Targeted Therapies in bladder cancer
    DOD Peer Reviewed Cancer Research Program CA240972Aug 1, 2025 - Jul 30, 2029
    Defining and exploiting the cancer surfaceome landscape for novel therapeutics
    Damon Runyon Cancer Foundation Clinical Investigator AwardJul 1, 2025 - Jun 30, 2028
    Role: Principal Investigator
    Defining the roles of PPARgamma and TGFbeta in regulating NECTIN4 and resistance to NECTIN4-targeting therapies
    NIH/NCI K08CA273514Sep 15, 2022 - Sep 15, 2027
    Role: Principal Investigator
    Discovering Precision Oncology Approaches for CDK12-Deficient Prostate Cancer
    Prostate Cancer Foundation 20YOUN06Jan 1, 2021 - Dec 31, 2024
    Role: Principal Investigator
    Understanding the Role of CDK12 and Identifying Immunotherapy and Synthetic Lethal Targeting Strategies
    Department of Defense W81XWH2010136Jul 1, 2020 - Jun 30, 2024
    Role: Principal Investigator
    The Role of Precision Therapy in the Treatment of CDK12 Altered Metastatic Prostate Cancer
    Prostate Cancer Foundation PCF 2020 Bristol-Myers Squibb-PCF
    Role: Co-Investigator
    Description: https://www.pcf.org/c/challenge-awards-class-of-2020/

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Autophagolysosomal exocytosis inverts Src kinase onto the cell surface in cancer. Science. 2026 Mar 12; 391(6790):eaec1778. Delaveris CS, Loudermilk RP, Pandey A, Remesh SG, Peters-Clarke TM, Ganjave SD, Dougherty WJN, Delavan HM, Wang C, Ling J, Camara Serrano JA, Salangsang F, Ding CC, Greenland N, Chu CE, Porten S, Steri V, Chou J, Evans MJ, Leung KK, Wells JA. PMID: 41818370.
      View in: PubMed   Mentions:
    2. Synergistic treatment of prostate cancer and multiple myeloma using CD46-targeted radioimmunotherapy-antibody drug conjugates. Clin Cancer Res. 2026 Jan 22. Bidkar AP, Bidlingmaier S, Wadhwa A, Mayne E, Raveendran A, Naik S, Xue C, Basak M, Bobba KN, Patiño-Escobar B, Greenland N, Camara Serrano JA, Steri V, Chou J, Wiita A, He J, Wilson DM, Aggarwal R, VanBrocklin HF, Seo Y, Liu B, Flavell RR. PMID: 41569419.
      View in: PubMed   Mentions:
    3. Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer. Nat Genet. 2025 Dec; 57(12):3027-3038. Li H, Melnyk JE, Fu BXH, Shrestha R, Zhang M, Sjöström M, Feng S, Anderson JA, Han W, Chesner LN, Shin HJ, Farsh T, Suarez HJ, Nath S, Chou J, Das R, Egusa EA, Calvert M, Kishishita A, Barpanda A, Zhu J, Maheshwari A, Chen WS, Alshalalfa M, Winters A, Hua JT, Liu T, Davicioni E, Wiita AP, Stohr BA, Siddiqui J, Huang B, Small EJ, Shokat KM, Nelson PS, Quigley DA, Wasmuth EV, Gilbert LA, Feng FY. PMID: 41193657; PMCID: PMC12695660.
      View in: PubMed   Mentions:
    4. Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer. Nat Commun. 2025 Sep 10; 16(1):8215. Chang K, Delavan HM, Yip E, Kasap C, Zhu J, Lodha R, Liao SY, Berman SC, Carretero-Gonzalez A, Basar M, Gokturk Ozcan G, Teo MY, Solit DB, Rosenberg JE, Al-Ahmadie H, Ding CCK, Chan E, Steri V, Porten SP, Koshkin VS, Friedlander TW, Feng FY, Lee JK, Wiita AP, Chu CE, Chou J. PMID: 40931013; PMCID: PMC12423289.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    5. Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy. Clin Cancer Res. 2025 Jul 15; 31(14):2963-2977. Bidkar AP, Peter R, Wadhwa A, Bobba KN, Bidlingmaier S, Meher N, Chou J, Greenland N, Dasari C, Naik S, Raveendran A, Basak M, Camara Serrano JA, Steri V, Kogan S, Oskowitz A, He J, Wilson DM, Aggarwal R, Sriram R, VanBrocklin HF, Seo Y, Liu B, Flavell RR. PMID: 39945595; PMCID: PMC12260511.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    6. Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression. Nat Commun. 2025 Jun 17; 16(1):5312. Yang H, Song H, Yip E, Gilpatrick T, Chang K, Allegakoen P, Lu KL, Hui K, Pham JH, Kasap C, Kumar V, Gayle J, Stohr BA, Cornelia Ding CK, Wiita AP, Meng MV, Chou J, Porten SP, Huang FW. PMID: 40527915; PMCID: PMC12174346.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    7. Defining CDK12 as a tumor suppressor and therapeutic target in mouse models of tubo-ovarian high-grade serous carcinoma. Proc Natl Acad Sci U S A. 2025 Jun 17; 122(24):e2426909122. Tien JC, Zhai Y, Wu R, Zhang Y, Chang Y, Cheng Y, Todd AJ, Wheeler CE, Li S, Mannan R, Cheng C, Magnuson B, Cruz G, Cao Y, Mahapatra S, Stolfi C, Cao X, Su F, Wang R, Yang J, Zhou L, Qiao Y, Xiao L, Cieslik M, Wang X, Wang Z, Chou J, Fearon ER, Ding K, Cho KR, Chinnaiyan AM. PMID: 40504161; PMCID: PMC12184368.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    8. Genome-wide CRISPR screens identify PTGES3 as a novel AR modulator. bioRxiv. 2025 May 31. Li H, Melnyk JE, Fu BXH, Shrestha R, Zhang M, Sjöström M, Feng S, Anderson JA, Han W, Chesner LN, Shin HJ, Farsh T, Suarez HJ, Nath S, Chou J, Das R, Egusa EA, Zhu J, Winters A, Maheshwari A, Hua JT, Alshalalfa M, Chen WS, Calvert M, Davicioni E, Kishishita A, Barpanda A, Liu T, Wiita AP, Stohr BA, Siddiqui J, Huang B, Small EJ, Shokat KM, Nelson P, Quigley DA, Wasmuth EV, Gilbert LA, Feng FY. PMID: 40501535; PMCID: PMC12154830.
      View in: PubMed   Mentions:
    9. Identification and Characterization of PLUTO-201, a Novel Long Non-Coding RNA Associated with Poor Outcomes in Prostate Cancer. bioRxiv. 2025 May 24. Li H, Younger NS, Malik B, Shin HJ, Zhang C, Niknafs Y, Zhao SG, Wilder-Romans K, Pitchiaya S, Han S, Barnard T, Lloyd P, Zhang M, Chesner LN, Calvert M, Egusa EA, Zhu J, Chou J, Das R, Kothari V, Shenoy T, Diolaiti ME, Malik R, Prensner JR, Burlingame A, Ashworth A, Chinnaiyan AM, Feng F, Li H. PMID: 40475527; PMCID: PMC12139821.
      View in: PubMed   Mentions:
    10. PET Imaging Using 89Zr-Labeled StarPEG Nanocarriers Reveals Heterogeneous Enhanced Permeability and Retention in Prostate Cancer. Mol Cancer Ther. 2025 Jan 02; 24(1):141-151. Meher N, Bidkar AP, Wadhwa A, Bobba KN, Dhrona S, Dasari C, Mu C, Fong COY, Cámara JA, Ali U, Basak M, Bulkley D, Steri V, Fontaine SD, Zhu J, Oskowitz A, Aggarwal RR, Sriram R, Chou J, Wilson DM, Seo Y, Santi DV, Ashley GW, VanBrocklin HF, Flavell RR. PMID: 39331510; PMCID: PMC11694059.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    11. Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors. Clin Cancer Res. 2024 Dec 02; 30(23):5445-5458. Chou J, Robinson TM, Egusa EA, Lodha R, Zhang M, Badura M, Mikayelyan M, Delavan HM, Swinderman J, Wilson C, Zhu J, Das R, Nguyen M, Loehr A, Golsorkhi T, Simmons A, Abida W, Chinnaiyan AM, Arkin MR, Small EJ, Quigley DA, Yang L, Kim M, Ashworth A, Feng FY. PMID: 39321214; PMCID: PMC11611633.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    12. Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer. Nat Cancer. 2024 Dec; 5(12):1885-1901. Yang Y, Badura ML, O'Leary PC, Delavan HM, Robinson TM, Egusa EA, Zhong X, Swinderman JT, Li H, Zhang M, Kim M, Ashworth A, Feng FY, Chou J, Yang L. PMID: 39558146; PMCID: PMC11671220.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    13. Patients Can Administer Mobile Audio Recordings to Increase Knowledge in Advanced Prostate Cancer. Cancer Med. 2024 Nov; 13(22):e70433. Kwon DH, Kwon DH, Trihy L, Darvish N, Hearst E, Sumra S, Borno HT, Bose R, Chou J, de Kouchkovsky I, Desai A, Ekstrand B, Friedlander T, Kaur G, Koshkin VS, Nesheiwat S, Sepucha K, Small EJ, Aggarwal RR, Belkora J. PMID: 39569542; PMCID: PMC11579662.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    14. CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13. Cell Rep Med. 2024 Oct 15; 5(10):101758. Tien JC, Luo J, Chang Y, Zhang Y, Cheng Y, Wang X, Yang J, Mannan R, Mahapatra S, Shah P, Wang XM, Todd AJ, Eyunni S, Cheng C, Rebernick RJ, Xiao L, Bao Y, Neiswender J, Brough R, Pettitt SJ, Cao X, Miner SJ, Zhou L, Wu YM, Labanca E, Wang Y, Parolia A, Cieslik M, Robinson DR, Wang Z, Feng FY, Chou J, Lord CJ, Ding K, Chinnaiyan AM. PMID: 39368479; PMCID: PMC11513839.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    15. HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains. Oncologist. 2024 Aug 05; 29(8):e1094-e1097. Zhu X, Chan E, Turski ML, Mendez CE, Hsu SC, Kumar V, Shipp C, Jindal T, Chang K, Onodera C, Devine WP, Grenert JP, Stohr BA, Ding CC, Stachler MD, Quigley DA, Feng FY, Chu CE, Porten SP, Chou J, Friedlander TW, Koshkin VS. PMID: 38908022; PMCID: PMC11299940.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    16. Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial. Clin Cancer Res. 2024 Aug 01; 30(15):3200-3210. Nguyen CB, Reimers MA, Perera C, Abida W, Chou J, Feng FY, Antonarakis ES, McKay RR, Pachynski RK, Zhang J, Reichert ZR, Palmbos PL, Caram MEV, Vaishampayan UN, Heath EI, Hopkins AC, Cieslik MP, Wu YM, Robinson DR, Baladandayuthapani V, Chinnaiyan AM, Alva AS. PMID: 38787530; PMCID: PMC11293970.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    17. CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality. bioRxiv. 2024 Mar 21. Tien JC, Chang Y, Zhang Y, Chou J, Cheng Y, Wang X, Yang J, Mannan R, Shah P, Wang XM, Todd AJ, Eyunni S, Cheng C, Rebernick RJ, Xiao L, Bao Y, Neiswender J, Brough R, Pettitt SJ, Cao X, Miner SJ, Zhou L, Wu YM, Labanca E, Wang Y, Parolia A, Cieslik M, Robinson DR, Wang Z, Feng FY, Lord CJ, Ding K, Chinnaiyan AM. PMID: 38562774; PMCID: PMC10983964.
      View in: PubMed   Mentions:
    18. Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer. J Nucl Med. 2024 02 01; 65(2):199-205. Koshkin VS, Kumar V, Kline B, Escobar D, Aslam M, Cooperberg MR, Aggarwal RR, de Kouchkovsky I, Chou J, Meng MV, Friedlander T, Porten S, Hope TA. PMID: 38212070; PMCID: PMC12530663.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    19. Development of CD46 targeted alpha theranostics in prostate cancer using 134Ce/225Ac-Macropa-PEG4-YS5. Theranostics. 2024; 14(4):1344-1360. Bobba KN, Bidkar AP, Wadhwa A, Meher N, Drona S, Sorlin AM, Bidlingmaier S, Zhang L, Wilson DM, Chan E, Greenland NY, Aggarwal R, VanBrocklin HF, He J, Chou J, Seo Y, Liu B, Flavell RR. PMID: 38389832; PMCID: PMC10879874.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    20. Large tandem duplications in cancer result from transcription and DNA replication collisions. medRxiv. 2024 Jan 10. Yang Y, Badura ML, O'Leary PC, Delavan HM, Robinson TM, Egusa EA, Zhong X, Swinderman JT, Li H, Zhang M, Kim M, Ashworth A, Feng FY, Chou J, Yang L. PMID: 38260434; PMCID: PMC10802642.
      View in: PubMed   Mentions:
    21. Central Nervous System Disease Progression Among Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Case Series. Clin Genitourin Cancer. 2024 04; 22(2):315-321. Shipp C, Jindal T, Chou J, Friedlander TW, Koshkin VS, Kumar V. PMID: 38114390; PMCID: PMC12172690.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    22. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. Lancet Oncol. 2023 11; 24(11):1266-1276. Aggarwal R, Starzinski S, de Kouchkovsky I, Koshkin V, Bose R, Chou J, Desai A, Kwon D, Kaushal S, Trihy L, Rastogi M, Ippisch R, Aslam M, Friedlander T, Feng F, Oh D, Cheung A, Small E, Evans M, Fong L, Hope TA. PMID: 37922930; PMCID: PMC10667020.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    23. The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer. Cancer Res. 2023 08 15; 83(16):2763-2774. Lundberg A, Zhang M, Aggarwal R, Li H, Zhang L, Foye A, Sjöström M, Chou J, Chang K, Moreno-Rodriguez T, Shrestha R, Baskin A, Zhu X, Weinstein AS, Younger N, Alumkal JJ, Beer TM, Chi KN, Evans CP, Gleave M, Lara PN, Reiter RE, Rettig MB, Witte ON, Wyatt AW, Feng FY, Small EJ, Quigley DA. PMID: 37289025; PMCID: PMC10425725.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    24. Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin. Clin Genitourin Cancer. 2023 10; 21(5):e394-e404. Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal R, Small EJ, Fong L, Chou J, Friedlander T, de Kouchkovsky I, Koshkin VS. PMID: 37316414.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    25. Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy. Clin Cancer Res. 2023 05 15; 29(10):1916-1928. Bidkar AP, Wang S, Bobba KN, Chan E, Bidlingmaier S, Egusa EA, Peter R, Ali U, Meher N, Wadhwa A, Dhrona S, Dasari C, Beckford-Vera D, Su Y, Tang R, Zhang L, He J, Wilson DM, Aggarwal R, VanBrocklin HF, Seo Y, Chou J, Liu B, Flavell RR. PMID: 36917693; PMCID: PMC10183825.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimals
    26. Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer. Front Oncol. 2023; 13:1161089. Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou J, Friedlander T, Koshkin VS. PMID: 37091148; PMCID: PMC10113661.
      View in: PubMed   Mentions: 7  
    27. Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer. Clin Cancer Res. 2023 04 03; 29(7):1232-1242. Chopra S, Trepka K, Sakhamuri S, Carretero-González A, Zhu J, Egusa E, Zhou J, Leung K, Zhao N, Hooshdaran N, Feng FY, Wells JA, Chou J, Evans MJ. PMID: 36648492; PMCID: PMC10073270.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    28. Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer. Cancer Res. 2023 01 18; 83(2):301-315. Chou J, Egusa EA, Wang S, Badura ML, Lee F, Bidkar AP, Zhu J, Shenoy T, Trepka K, Robinson TM, Steri V, Huang J, Wang Y, Small EJ, Chan E, Stohr BA, Ashworth A, Delafontaine B, Rottey S, Cooke KS, Hashemi Sadraei N, Yu B, Salvati M, Bailis JM, Feng FY, Flavell RR, Aggarwal R. PMID: 36351060; PMCID: PMC10263373.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimals
    29. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers. Urol Oncol. 2023 03; 41(3):145.e7-145.e15. Kwon DH, Shakhnazaryan N, Shui D, Hong JC, Mohamad O, de Kouchkovsky I, Borno HT, Bose R, Chou J, Desai A, Fong L, Friedlander TW, Koshkin VS, Aggarwal RR, Feng FY, Hope TA, Small EJ. PMID: 36435709.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    30. The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. Cancer Res. 2022 11 02; 82(21):3888-3902. Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, Fraser M, Chesner L, Perry MD, Moreno-Rodriguez T, Chen WS, Alumkal JJ, Chou J, Morgans AK, Beer TM, Thomas GV, Gleave M, Lloyd P, Phillips T, McCarthy E, Haffner MC, Zoubeidi A, Annala M, Reiter RE, Rettig MB, Witte ON, Fong L, Bose R, Huang FW, Luo J, Bjartell A, Lang JM, Mahajan NP, Lara PN, Evans CP, Tran PT, Posadas EM, He C, Cui XL, Huang J, Zwart W, Gilbert LA, Maher CA, Boutros PC, Chi KN, Ashworth A, Small EJ, He HH, Wyatt AW, Quigley DA, Feng FY. PMID: 36251389; PMCID: PMC9627125.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    31. Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2. Cancer Res. 2022 11 02; 82(21):3950-3961. O'Leary PC, Chen H, Doruk YU, Williamson T, Polacco B, McNeal AS, Shenoy T, Kale N, Carnevale J, Stevenson E, Quigley DA, Chou J, Feng FY, Swaney DL, Krogan NJ, Kim M, Diolaiti ME, Ashworth A. PMID: 36273492; PMCID: PMC9633439.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    32. CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease. Clin Cancer Res. 2022 07 15; 28(14):3066-3075. Zhao N, Chopra S, Trepka K, Wang YH, Sakhamuri S, Hooshdaran N, Kim H, Zhou J, Lim SA, Leung KK, Egusa EA, Zhu J, Zhang L, Foye A, Sriram R, Chan E, Seo Y, Feng FY, Small EJ, Chou J, Wells JA, Aggarwal R, Evans MJ. PMID: 35604681; PMCID: PMC9288514.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimals
    33. APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer. Front Oncol. 2022; 12:816706. Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J, Friedlander T, Fong L, Small EJ, Sweet-Cordero A, Koshkin VS. PMID: 35321431; PMCID: PMC8935010.
      View in: PubMed   Mentions: 9  
    34. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. Eur Urol Oncol. 2022 12; 5(6):714-718. Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY. PMID: 35216942; PMCID: PMC10262920.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    35. Repeat Treatment of Patients With Advanced Urothelial Carcinoma With Immune Checkpoint Inhibitors Following Prior Progression on a Checkpoint Inhibitor Regimen: A Case Series. Clin Genitourin Cancer. 2022 04; 20(2):189-194. Jindal T, Chou J, Friedlander T, Barata PC, Koshkin VS. PMID: 34998700.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    36. Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer. 2022 Mar 15; 128(6):1194-1205. Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS. PMID: 34882781.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    37. An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer. Nat Commun. 2021 07 29; 12(1):4601. Das R, Sjöström M, Shrestha R, Yogodzinski C, Egusa EA, Chesner LN, Chen WS, Chou J, Dang DK, Swinderman JT, Ge A, Hua JT, Kabir S, Quigley DA, Small EJ, Ashworth A, Feng FY, Gilbert LA. PMID: 34326322; PMCID: PMC8322386.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    38. Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. Clin Cancer Res. 2021 09 15; 27(18):5123-5130. Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J. PMID: 34108177; PMCID: PMC8634828.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansCells
    39. TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor. J Immunother Cancer. 2021 05; 9(5). de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, Koshkin VS. PMID: 33980590; PMCID: PMC8118032.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    40. Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. Eur Urol. 2021 06; 79(6):717-721. Chu CE, Alshalalfa M, Sjöström M, Zhao SG, Liu Y, Chou J, Herlemann A, Mahal B, Kishan AU, Spratt DE, Cooperberg M, Small E, Wong A, Porten S, Hope TA, Ross AE, Davicioni E, Nguyen P, Karnes RJ, Carroll PR, Schaeffer E, Feng FY. PMID: 33840559.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    41. Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer. Cancer. 2021 06 15; 127(12):1965-1973. Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS. PMID: 33690902.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    42. Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET. Clin Cancer Res. 2021 03 01; 27(5):1305-1315. Wang S, Li J, Hua J, Su Y, Beckford-Vera DR, Zhao W, Jayaraman M, Huynh TL, Zhao N, Wang YH, Huang Y, Qin F, Shen S, Gioeli D, Dreicer R, Sriram R, Egusa EA, Chou J, Feng FY, Aggarwal R, Evans MJ, Seo Y, Liu B, Flavell RR, He J. PMID: 33293372; PMCID: PMC7925362.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    43. Molecular Insights in Transmission of Cancer From an Organ Donor to Four Transplant Recipients. J Natl Compr Canc Netw. 2020 11; 18(11):1446-1452. Atreya CE, Collisson EA, Park M, Grenert JP, Behr SC, Gonzalez A, Chou J, Maisel S, Friedlander TW, Freise CE, Shoji J, Semrad TJ, Van Ziffle J, Chin-Hong P. PMID: 33152701.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    44. Autoantibody Landscape in Patients with Advanced Prostate Cancer. Clin Cancer Res. 2020 12 01; 26(23):6204-6214. Chen WS, Haynes WA, Waitz R, Kamath K, Vega-Crespo A, Shrestha R, Zhang M, Foye A, Baselga Carretero I, Perez Garcilazo I, Zhang M, Zhao SG, Sjöström M, Quigley DA, Chou J, Beer TM, Rettig M, Gleave M, Evans CP, Lara P, Chi KN, Reiter RE, Alumkal JJ, Ashworth A, Aggarwal R, Small EJ, Daugherty PS, Ribas A, Oh DY, Shon JC, Feng FY. PMID: 32967941; PMCID: PMC7710628.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    45. The DNA methylation landscape of advanced prostate cancer. Nat Genet. 2020 08; 52(8):778-789. Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, Zhang L, Alshalalfa M, Laura Chang S, Houlahan KE, Shiah YJ, Beer TM, Thomas G, Chi KN, Gleave M, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Yvonne Kim M, Fong L, Spratt DE, Morgan TM, Bose R, Huang FW, Li H, Chesner L, Shenoy T, Goodarzi H, Asangani IA, Sandhu S, Lang JM, Mahajan NP, Lara PN, Evans CP, Febbo P, Batzoglou S, Knudsen KE, He HH, Huang J, Zwart W, Costello JF, Luo J, Tomlins SA, Wyatt AW, Dehm SM, Ashworth A, Gilbert LA, Boutros PC, Farh K, Chinnaiyan AM, Maher CA, Small EJ, Quigley DA, Feng FY. PMID: 32661416; PMCID: PMC7454228.
      View in: PubMed   Mentions: 190     Fields:    Translation:HumansCells
    46. Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy. Cancer Discov. 2020 03; 10(3):351-370. Chou J, Quigley DA, Robinson TM, Feng FY, Ashworth A. PMID: 32071145.
      View in: PubMed   Mentions: 152     Fields:    Translation:HumansCells
    47. MMP9 modulates the metastatic cascade and immune landscape for breast cancer anti-metastatic therapy. Life Sci Alliance. 2019 12; 2(6). Owyong M, Chou J, van den Bijgaart RJ, Kong N, Efe G, Maynard C, Talmi-Frank D, Solomonov I, Koopman C, Hadler-Olsen E, Headley M, Lin C, Wang CY, Sagi I, Werb Z, Plaks V. PMID: 31727800; PMCID: PMC6856766.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansAnimalsCells
    48. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. Eur Urol. 2020 03; 77(3):333-341. Reimers MA, Yip SM, Zhang L, Cieslik M, Dhawan M, Montgomery B, Wyatt AW, Chi KN, Small EJ, Chinnaiyan AM, Alva AS, Feng FY, Chou J. PMID: 31640893; PMCID: PMC7365609.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    49. DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. Clin Cancer Res. 2019 09 15; 25(18):5608-5622. Kothari V, Goodwin JF, Zhao SG, Drake JM, Yin Y, Chang SL, Evans JR, Wilder-Romans K, Gabbara K, Dylgjeri E, Chou J, Sun G, Tomlins SA, Mehra R, Hege K, Filvaroff EH, Schaeffer EM, Karnes RJ, Quigley DA, Rathkopf DE, He HH, Speers C, Spratt DE, Gilbert LA, Ashworth A, Chinnaiyan AM, Raj GV, Knudsen KE, Feng FY. PMID: 31266829; PMCID: PMC6744969.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    50. Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. Clin Cancer Res. 2019 04 15; 25(8):2450-2457. Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, Quigley DA, Dang HX, Barnard TJ, Mahal BA, Gibb EA, Liu Y, Davicioni E, Duska LR, Posadas EM, Jolly S, Spratt DE, Nguyen PL, Maher CA, Small EJ, Feng FY. PMID: 30573691.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    51. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 10 18; 175(3):889. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. PMID: 30340047.
      View in: PubMed   Mentions: 76     Fields:    
    52. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 07 26; 174(3):758-769.e9. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. PMID: 30033370; PMCID: PMC6425931.
      View in: PubMed   Mentions: 357     Fields:    Translation:HumansCells
    53. Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell. 2018 06 14; 173(7):1770-1782.e14. Wu YM, Cieslik M, Lonigro RJ, Vats P, Reimers MA, Cao X, Ning Y, Wang L, Kunju LP, de Sarkar N, Heath EI, Chou J, Feng FY, Nelson PS, de Bono JS, Zou W, Montgomery B, Alva A, PCF/SU2C International Prostate Cancer Dream Team, Robinson DR, Chinnaiyan AM. PMID: 29906450; PMCID: PMC6084431.
      View in: PubMed   Mentions: 292     Fields:    Translation:HumansCells
    54. Prostate cancer in the era of "Omic" medicine: recognizing the importance of DNA damage repair pathways. Ann Transl Med. 2018 May; 6(9):161. Kornberg Z, Chou J, Feng FY, Ryan CJ. PMID: 29911109; PMCID: PMC5985268.
      View in: PubMed   Mentions: 7  
    55. HIF signaling in osteoblast-lineage cells promotes systemic breast cancer growth and metastasis in mice. Proc Natl Acad Sci U S A. 2018 01 30; 115(5):E992-E1001. Devignes CS, Aslan Y, Brenot A, Devillers A, Schepers K, Fabre S, Chou J, Casbon AJ, Werb Z, Provot S. PMID: 29339479; PMCID: PMC5798374.
      View in: PubMed   Mentions: 51     Fields:    Translation:AnimalsCells
    56. GATA3 targets semaphorin 3B in mammary epithelial cells to suppress breast cancer progression and metastasis. Oncogene. 2017 10 05; 36(40):5567-5575. Shahi P, Wang CY, Chou J, Hagerling C, Gonzalez Velozo H, Ruderisch A, Yu Y, Lai MD, Werb Z. PMID: 28581515; PMCID: PMC5629104.
      View in: PubMed   Mentions: 30     Fields:    Translation:AnimalsCells
    57. Respiratory Failure in a Woman 8 Months After an Allogeneic Stem Cell Transplant. JAMA Oncol. 2016 Dec 01; 2(12):1651-1652. Chou J, Wallender E, Schwartz BS. PMID: 27559706.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    58. Electrocardiography Evolution in a Woman Presenting With Alcohol Withdrawal Seizures and Cocaine Use. JAMA Intern Med. 2016 05 01; 176(5):693-5. Chou J, Beutler LR, Goldschlager N. PMID: 27019877.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    59. Metalloproteinases: a Functional Pathway for Myeloid Cells. Microbiol Spectr. 2016 04; 4(2). Chou J, Chan MF, Werb Z. PMID: 27227311; PMCID: PMC4888795.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    60. The Transcriptional Repressor ZNF503/Zeppo2 Promotes Mammary Epithelial Cell Proliferation and Enhances Cell Invasion. J Biol Chem. 2015 Feb 06; 290(6):3803-13. Shahi P, Slorach EM, Wang CY, Chou J, Lu A, Ruderisch A, Werb Z. PMID: 25538248; PMCID: PMC4319044.
      View in: PubMed   Mentions: 25     Fields:    Translation:AnimalsCells
    61. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014 Dec; 15(12):786-801. Bonnans C, Chou J, Werb Z. PMID: 25415508; PMCID: PMC4316204.
      View in: PubMed   Mentions: 2010     Fields:    Translation:HumansAnimalsCells
    62. microRNA-mediated regulation of the tumor microenvironment. Cell Cycle. 2013 Oct 15; 12(20):3262-71. Chou J, Shahi P, Werb Z. PMID: 24036551; PMCID: PMC3885637.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCells
    63. GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. Nat Cell Biol. 2013 Feb; 15(2):201-13. Chou J, Lin JH, Brenot A, Kim JW, Provot S, Werb Z. PMID: 23354167; PMCID: PMC3660859.
      View in: PubMed   Mentions: 221     Fields:    Translation:HumansAnimalsCells
    64. MicroRNAs play a big role in regulating ovarian cancer-associated fibroblasts and the tumor microenvironment. Cancer Discov. 2012 Dec; 2(12):1078-80. Chou J, Werb Z. PMID: 23230184; PMCID: PMC3531831.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    65. The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression. Cancer Discov. 2012 Jul; 2(7):638-51. Littlepage LE, Adler AS, Kouros-Mehr H, Huang G, Chou J, Krig SR, Griffith OL, Korkola JE, Qu K, Lawson DA, Xue Q, Sternlicht MD, Dijkgraaf GJ, Yaswen P, Rugo HS, Sweeney CA, Collins CC, Gray JW, Chang HY, Werb Z. PMID: 22728437; PMCID: PMC3546490.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansAnimalsCells
    66. Zeppo1 is a novel metastasis promoter that represses E-cadherin expression and regulates p120-catenin isoform expression and localization. Genes Dev. 2011 Mar 01; 25(5):471-84. Slorach EM, Chou J, Werb Z. PMID: 21317240; PMCID: PMC3049288.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansAnimalsCells
    67. GATA3 in development and cancer differentiation: cells GATA have it! J Cell Physiol. 2010 Jan; 222(1):42-9. Chou J, Provot S, Werb Z. PMID: 19798694; PMCID: PMC2915440.
      View in: PubMed   Mentions: 142     Fields:    Translation:HumansAnimals
    68. Gigaxonin-controlled degradation of MAP1B light chain is critical to neuronal survival. Nature. 2005 Nov 10; 438(7065):224-8. Allen E, Ding J, Wang W, Pramanik S, Chou J, Yau V, Yang Y. PMID: 16227972.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansAnimalsCells
    Jonathan's Networks
    Concepts (280)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (109)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-21-g9d46e6c4 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.